廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,041.17
    +30.50 (+1.01%)
     
  • 滬深300

    3,537.48
    +16.52 (+0.47%)
     
  • 美元

    7.8252
    -0.0004 (-0.01%)
     
  • 人民幣

    0.9222
    -0.0006 (-0.07%)
     
  • 道指

    39,807.37
    +47.29 (+0.12%)
     
  • 標普 500

    5,254.35
    +5.86 (+0.11%)
     
  • 納指

    16,379.46
    -20.06 (-0.12%)
     
  • 日圓

    0.0515
    +0.0000 (+0.02%)
     
  • 歐元

    8.4434
    +0.0028 (+0.03%)
     
  • 英鎊

    9.8690
    -0.0070 (-0.07%)
     
  • 紐約期油

    83.11
    -0.06 (-0.07%)
     
  • 金價

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin

    70,305.99
    -396.11 (-0.56%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Why Merrimack Shares Are Surging Over 200% Today?

  • Ipsen SA (OTC: IPSEY) announced that the Phase 3 NAPOLI 3 trial of Onivyde plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) met its primary endpoint.

  • The combination therapy demonstrated a clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

  • Progression-free survival (PFS) also showed significant improvement over the comparator arm.

  • In reaction to the news, Merrimack Pharmaceuticals Inc (NASDAQ: MACK) shares are up over 200%.

  • In 2017, Ipsen gained exclusive commercialization rights for the current and potential future indications of Merrimack's pancreatic cancer drug Onivyde.

  • Ipsen agreed to pay $575 million cash at closing plus up to $450 million upon the approval of potential additional indications for Onivyde in the U.S.

  • In August, the companies reported a primary analysis of the Phase 3 trial of Onivyde for second-line small cell lung cancer (SCLC).

  • The study did not meet the primary endpoint of overall survival in patients treated with Onivyde versus topotecan.

  • However, a doubling of the secondary endpoint of the objective response rate in favor of Onivyde was observed.

  • Price Action: MACK shares are up 243% at $13.72 during the premarket session on the last check Wednesday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.